Lisofylline

Lisofylline

SCHEMBL6878645

[2H]C([2H])(CCCn1c(=O)c2c(ncn2C)n(C)c1=O)[C@H](C)O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 7/20 0.65
TNF P01375 3/20 0.65
ACHE P22303 2/20 0.65
USP2 O75604 1/20 0.65
LMNA P02545 1/20 0.65
CYP1A2 P05177 1/20 0.65
TSHR P16473 1/20 0.65
NFKB1 P19838 1/20 0.65
PDE4A P27815 1/20 0.65
PMP22 Q01453 1/20 0.65
PDE4B Q07343 1/20 0.65
PDE4C Q08493 1/20 0.65
PDE4D Q08499 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
RXFP1 Q9HBX9 1/20 0.65
CHIT1 Q13231 1/20 0.56
CHIA Q9BZP6 1/20 0.56
AKR1B1 P15121 1/20 0.54
PIK3CD O00329 1/20 0.54
POLB P06746 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lisofylline SCHEMBL6879511 1.00 ADORA2B (0.65) ADORA2BTNFACHEUSP2LMNA
Lisofylline SCHEMBL6878616 1.00 ADORA2B (0.65) ADORA2BTNFACHEUSP2LMNA
Lisofylline SCHEMBL15423008 0.94 ADORA2B (0.58) ADORA2BTNFACHEUSP2LMNA
Lisofylline SCHEMBL15341003 0.94 ADORA2B (0.58) ADORA2BTNFACHEUSP2LMNA
Lisofylline SCHEMBL15341009 0.94 ADORA2B (0.58) ADORA2BTNFACHEUSP2LMNA
Lisofylline SCHEMBL15423038 0.94 ADORA2B (0.58) ADORA2BTNFACHEUSP2LMNA
Lisofylline SCHEMBL173236 0.93 ADORA2B (0.62) ADORA2BTNFACHEUSP2LMNA
Pcs-499 SCHEMBL173235 0.93 ADORA2B (0.62) ADORA2BTNFACHEUSP2LMNA
Lisofylline SCHEMBL6876106 0.93 ADORA2B (0.62) ADORA2BTNFACHEUSP2LMNA
Lisofylline SCHEMBL6879564 0.92 ADORA2B (0.63) ADORA2BTNFACHEUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130280768-A1 PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION CONCERT PHARMACEUTICALS, INC. (US) 2013-10-24 US disclosed
US-8263601-B2 Deuterium substituted xanthine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2012-09-11 US disclosed
US-20120202830-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2012-08-09 US disclosed
US-20110077255-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2011-03-31 US disclosed
US-20110059995-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS INC. 2011-03-10 US disclosed
US-20110053961-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077255-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 ADORA2B 60/4885TNF 583/4885ACHE 945/4885
US-20110053961-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 ADORA2B 60/4885TNF 583/4885ACHE 945/4885
US-20120202830-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 ADORA2B 60/4885TNF 583/4885ACHE 945/4885
US-20110059995-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 ADORA2B 60/4885TNF 583/4885ACHE 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.